RxDoctor Payments Data

Jason Breed, MD

Family Medicine · Yukon, OKNPI 1821301011

Payments from drug & device makers

$6,922in general payments, 2019–2025

Across 509 payments — averaging $13.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$920
  • Pfizer$706
  • GSK$608
  • Boehringer Ingelheim$517
  • Novo Nordisk$479
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,910100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,922 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$106,044
Medicare patients
246
Services billed
2,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide146$173,327
EliquisApixaban115$125,598
OzempicSemaglutide73$97,885
JardianceEmpagliflozin30$47,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$44,162
TrulicityDulaglutide12$21,580
JanumetSitagliptin Phos/Metformin Hcl17$21,445
JanuviaSitagliptin Phosphate11$17,201
XareltoRivaroxaban27$17,200
Janumet XrSitagliptin Phos/Metformin Hcl12$15,847
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$15,634
GlyxambiEmpagliflozin/Linagliptin14$14,332
Breo ElliptaFluticasone/Vilanterol19$12,567
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,815
Victoza 3-PakLiraglutide11$8,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$920$194,907158 claims
PfizerEliquis$706$125,598115 claims
Novo NordiskOzempic$479$97,88573 claims
Boehringer IngelheimJardiance, Glyxambi$517$62,03544 claims
GSKTrelegy Ellipta, Breo Ellipta$608$56,72952 claims
MerckJanumet, Januvia, Janumet Xr$266$54,49440 claims
Johnson & JohnsonXarelto$117$17,20027 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$4,679390 claims
AbbVieSynthroid$1,002$2,16723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →